Aventis Arava Labeling Update Expected Based On Methotrexate Combo Study
Executive Summary
Aventis is working with FDA to update Arava labeling based on postmarketing information from methotrexate combination studies on the rheumatoid arthritis drug
You may also be interested in...
FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks
Agency’s assessment of teriflunomide for multiple sclerosis incorporated the known safety data for leflunomide, a chemically related drug with an extensive post-marketing record in rheumatoid arthritis. Despite hepatotoxicity and other safety concerns with the older drug, its clinical experience provided reassurance that Aubagio’s risks could be managed without a REMS.
Aventis Arava Liver Toxicity Warning Is Satisfactory, FDA Arthritis Cmte. Says
Aventis' existing labeled warnings for Arava regarding liver toxicity do not need to be strenghened, members of FDA's Arthritis Advisory Committee told the agency at its March 5 safety review of the arthritis drug
Aventis Arava Liver Toxicity Warning Is Satisfactory, FDA Arthritis Cmte. Says
Aventis' existing labeled warnings for Arava regarding liver toxicity do not need to be strenghened, members of FDA's Arthritis Advisory Committee told the agency at its March 5 safety review of the arthritis drug